Avelumab belongs to a class of drugs called checkpoint inhibitors. These drugs work by targeting specific proteins that regulate the immune system. PD-L1 is one of these proteins, and it is often overexpressed on the surface of cancer cells. When PD-L1 binds to its receptor, PD-1, on T-cells, it sends a signal that inhibits the immune response. Avelumab blocks this interaction, allowing T-cells to remain active and attack cancer cells.
